Skip to main content
SpringerLink
Log in

Adalimumab/infliximab/rituximab

Various toxicities following off-label therapy: 5 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Dominguez-Casas LC, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Seminars in Arthritis and Rheumatism 50: 608-615, No. 4, Aug 2020. Available from: URL: http://doi.org/10.1016/j.semarthrit.2020.03.023

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab/rituximab. Reactions Weekly 1810, 16 (2020). https://doi.org/10.1007/s40278-020-80036-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-80036-5

Search

Navigation